Effects of a single course of deferoxamine in neuroblastoma patients

Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M.A.; Helson, L.

Cancer Research 50(16): 4929-4930

1990


ISSN/ISBN: 0008-5472
PMID: 2379156
Document Number: 351294
A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed. Within 2 days of completion of treatment responses were observed in 7 of 9 patients and there was no drug toxicity. These responses were a decrease in bone marrow infiltration and, in one patient, a measurable reduction in her tumor mass. We conclude that deferoxamine given as an 8-h i.v. infusion daily for 5 days at 150 mg/kg/day has antitumor activity.

Document emailed within 1 workday
Secure & encrypted payments